Tsinghua Science and Technology
Volume 19

Issue 3

Article 6

2014

An Integrated Workflow for Proteome-Wide Off-Target
Identification and Polypharmacology Drug Design
Thomas Evangelidis
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of
Athens, Athens, Greece.

Lei Xie
Department of Computer Science, Hunter College, The Graduate Center, The City University of New York,
NY 10065, USA.

Follow this and additional works at: https://tsinghuauniversitypress.researchcommons.org/tsinghuascience-and-technology
Part of the Computer Sciences Commons, and the Electrical and Computer Engineering Commons

Recommended Citation
Thomas Evangelidis, Lei Xie. An Integrated Workflow for Proteome-Wide Off-Target Identification and
Polypharmacology Drug Design. Tsinghua Science and Technology 2014, 19(03): 275-284.

This Research Article is brought to you for free and open access by Tsinghua University Press: Journals Publishing.
It has been accepted for inclusion in Tsinghua Science and Technology by an authorized editor of Tsinghua
University Press: Journals Publishing.

TSINGHUA SCIENCE AND TECHNOLOGY
ISSNll1007-0214ll06/11llpp275-284
Volume 19, Number 3, June 2014

An Integrated Workflow for Proteome-Wide Off-Target Identification
and Polypharmacology Drug Design
Thomas Evangelidis and Lei Xie
Abstract: Polypharmacology, which focuses on designing drugs to target multiple receptors, has emerged as a new
paradigm in drug discovery. To rationally design multi-target drugs, it is fundamental to understand protein-ligand
interactions on a proteome scale. We have developed a Proteome-wide Off-target Pipeline (POP) that integrates
ligand binding site analysis, protein-ligand docking, the statistical analysis of docking scores, and electrostatic
potential calculations. The utility of POP is demonstrated by a case study, in which the molecular mechanism of
anti-cancer effect of Nelfinavir is hypothesized. By combining structural proteome-wide off-target identification and
systems biology, it is possible for us to correlate drug perturbations with clinical outcomes.
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1

Introduction

In the conventional drug discovery process, a
reductionist model of “one-drug-one-gene” is widely
adopted in the pharmaceutical industry. Drugs are
screened or designed to modify the activity of a single
disease-causing gene or its encoded protein, which
is termed as drug target (or “on-target”). However,
unexpected drug-target interactions often exist[1] . The
unexpected gene (or protein) involved in the drug action
is categorized as “off-target”. The off-target may cause
unwanted drug side effects. This is highlighted in a
recent withdrawal of Torcetrapib from phase III clinical
trial. Torcetrapib is intended to lower cholesterol, thus
reduce the risk of heart disease. Unfortunately, it causes
serious side effect of heart attack due to unexpected
off-target effects. On the other hand, the off-target is
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beneficial. One drug X designed for disease A can
be used to treat another disease B, if the off-target of
the drug X happens to be responsible for the disease
B. Drug repurposing (or repositioning) is a practice to
reuse existing drugs for new purposes[2] . Moreover, in
contrast to “one-drug-one-gene” paradigm, multi-target
therapies (also called polypharmacology) are needed
to treat systematic diseases such as cancer, given
the observed robustness and resilience of complex
biological networks to single drug treatments. In
principal, multi-target therapeutics can exhibit greater
efficacy and be less vulnerable to drug resistance
by impacting multiple nodes at the system level.
Indeed, a large number of the existing anti-infectious
and anti-cancer therapeutics is either multi-target
agents developed through drug combination or single
multi-target drugs discovered serendipitously. While
it is clear that a multi-target therapy enhances clinical
efficacy, there is an increased possibility of serious side
effects. Thus it remains a great challenge to rationally
design effective multi-target therapies.
One of central topic in polypharmacology is to
identify drug-target interactions on a proteome-scale. A
large number of drug-target interactions is already
known, and has been collected in the databases
such Protein Data Bank (PDB)[3] , DrugBank[4] ,
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PubChem[5, 6] , and ChEMBL[7] . Taking advantage
of existing knowledge on the on-target, multi-target
drug design can be reformulated as a proteome-wide
off-target identification problem. Given a validated ontarget, what are its off-targets within and across human
and pathogen proteomes? A number of methodologies
have been developed to answer this question. Relevant
proteins can be identified through their ligand
chemistry[8, 9] , biological profiles (e.g., binding
activities[5] , expression profiles[10] , or side effects[11] ),
and promiscuities based on their sequence, structure,
and ligand binding site similarity[12] . Moreover,
advances in genome sequencing and systems biology
have made it possible to reconstruct, model, and
simulate metabolic, signal transduction, and regulation
pathways of human and a large number of pathogens. A
review of related computational techniques can be
found in Ref. [1]. Recently, we have successfully
applied this combination of off-target identification
and systems biology to reuse safe pharmaceuticals
to treat multi-drug and extremely drug resistance
tuberculosis[13] and to reduce bacterial infections[14] ,
identify drug leads to target multiple receptors in
T. bruci[15] , predict side effect profiles for several
major pharmaceuticals[16, 17] , propose molecular
mechanisms of anti-cancer effect of anti-AIDS drug
Nelfinavir[18] , understand the genetic disposition of
drug responses[19] , and reconstruct structural proteome
scale drug-target network of M. tuberculosis genome
Drugome/TB[20] . These works have demonstrated
the power of integrating ligand binding comparison,
protein-ligand docking, surface electrostatic potential
analysis, Molecular Dynamics (MD) simulation,
and various functional genomics techniques in the
polypharmacology.
In spite of the success of aforementioned integrative
strategy, each component in the computational pipeline
was carried out sequentially and manually in the
previous studies. A user friendly software that is able
to predict off-targets through automatically linking
multiple algorithms will be extremely useful. In this
paper, we describe a Proteome-wide Off-target Pipeline
(POP) that will facilitate drug off-target identification
and polypharmacology drug design. POP implements
the proven successful algorithms for ligand binding
site characterization and comparison, protein-ligand
docking, statistical analysis of docking scores, and
electrostatic potential calculations. The details of
individual algorithms and their performance evaluations
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can be found in Refs. [13-23]. In addition, we present
a case study that applies POP to the identification of
human targets of anti-AIDS drug Nelfinavir. We find
new evidences to support that the anti-cancer effect of
Nelfinavir comes from its interactions with multiple
human protein kinases, as suggested in our previous
studies[18] . By combining POP with biological network
reconstruction and systems biology simulation, we
are able to correlate molecular interactions to clinical
outcomes. POP is free for academic users, available
from https://sites.google.com/site/offtargetpipeline/.

2
2.1

Methods
Overview

The workflow of POP is outlined in Fig. 1. One of
the core components in POP is software SMAP for
ligand binding site characterization and analysis, which
is available from http://funsite.sdsc.edu[21, 22] . The
premise is that similar ligand binding sites between
two proteins will bind to similar ligands. First, the
location and the boundary of the ligand binding site in
the given on-target is determined from the co-crystal

Fig. 1

A proteome-wide off-target pipeline.
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structure or predicted by the pocket detection algorithm
using SMAP. Subsequently, SMAP characterizes the
properties of the binding site by the Geometric Potential
(GP)[21] and evolutionary profile[22] . The electrostatic
potential of the binding site is calculated using
software APBS[24] . The delineation of the binding site
significantly reduces the search space for the structure
comparison made during the next step. Second, SMAP
searches the delineated binding site against all 3-D
structures in a given proteome, either experimental
determined or homology modeled, using a SequenceOrder Independent Profile-Profile Alignment (SOIPPA)
algorithm[22] , which is implemented in SMAP. SOIPPA
is able to detect similar ligand binding sites between
two structurally un-related proteins. The statistical
significance of the matched ligand binding site
similarity is estimated by an Extreme Value Distribution
mode[23] . Thus off-targets with similar ligand binding
sites to the on-target are identified. Third, SMAP
superimposes the ligand binding site of the on-target
and its bound ligand onto those top-ranked off-targets,
thus predicts an initial binding pose for the ligand
bound to each off-target. Finally, starting from the
superimposed binding pose and the predicted ligand
binding site for the off-targets, protein-ligand docking
software Surflex[25] , AutoDock 4[26] , and AutoDock
Vina[27] , all of which are free for academic users,
are applied to further optimize the binding pose. The
predicted binding affinity is normalized by the size
of ligands and the nature of receptors using a novel
statistical model for the protein-ligand docking score
(details below). In addition, the electrostatic potential
binding energy and similarity between the binding sites
can be calculated based on the binding pose of the
ligand.
2.2

Parallelization of SMAP

SMAP consists of three major steps as follows. (1) The
protein structure is characterized by a geometric
potential, a shape descriptor using the reduced C˛ only
structure representation[22] . It has been shown that both
the location and the boundary of the ligand binding
site can be accurately predicted by GP[21] . Moreover,
the reduced representation of the protein structure
makes the algorithm tolerant to protein flexibility
and experimental uncertainty, thus SMAP can be
applied to low resolution structures and homology
models. (2) Two structures are aligned using an SOIPPA
algorithm[22] . SOIPPA finds the most similar local
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patch in the spirit of local sequence alignment but
independent of the sequence order. This feature makes
SMAP not only appropriate for practical problems since
typically the boundary of the ligand binding site is not
clearly defined and depends on the bound ligand, but
also able to detect novel functional relationships across
fold space. (3) The aligned surface patches are ranked
by a scoring function that combines evolutionary,
geometric, and physical information. Moreover, we
have developed a new Extreme Value Distribution
(EVD) statistical model that can rapidly estimate
the statistical significance of the match between two
ligand binding sites[23] . In a benchmark evaluation,
SMAP outperformed existing algorithms for both ligand
binding site alignment quality and database search
sensitivity and specificity[22] . The ability of SMAP to
establish cross-fold ligand binding relationships and
its applications in drug discovery has been validated
experimentally by several recent studies, for example,
reuse of protein kinase inhibitors to target bacterial
carboxyl-transferases[22, 28] . In another study, the safe
pharmaceutical Entacapone, which targets human
COMT for Parkinsons disease, has been predicted and
validated to directly inhibit M. Tuberculosis InhA, the
most used drug target to treat tuberculosis[13] . Most
recently, we have applied SMAP to identify targetdrug interaction networks of pathogen P. aeruginosa.
We have predicted that the estrogen receptor ligand
binding site is significantly similar to that of two
virulence factor genes responsible for the infection
of P. aeruginosa. Subsequent experiments show that
Selective Estrogen Receptor Modulators (SERMs) are
able to increase the survival rate of C. elegans that are
infected by P. aeruginosa by reducing the production
of virulence factors[14] . Although SMAP is proven to be
efficient and robust, parallelization can further improve
its performance for genome-wide ligand binding site
comparisons. Moreover the software requires either
the 3-D structure per se, or a pre-built SMAP object
file. To avoid excessive disk space occupation, these
3-D coordinate and metadata files often need to
be downloaded from Protein Data Bank web server
(http://www.rcsb.org) before SMAP initiates the actual
calculations. POP offers a further boost in performance
by downloading PDB files needed for forthcoming
calculations, while constantly running a preset number
of jobs (the thread-pool size). Upon completion, the
structural proteome is prioritized according to the
predicted SMAP p-value of the ligand binding site
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match, and an arbitrary number of highly-scored
proteins is retained to undergo explicit docking with
the molecule of interest. SMAP also superimposes the
predicted off-target binding site to that in the on-target,
thus provides an initial binding pose of ligand in the
off-target.
2.3

Protein-ligand docking and statistical model
for docking score normalization

Currently, three docking programs are supported,
Surflex[25] , AutoDock 4[26] , and AutoDock Vina[27] .
These programs implement different scoring functions
and have varying computation times. Following
completion of docking, the set of proteins can be sorted
according to docking score. Although docking is able
to generate reliable binding poses, most of the time,
efficient, and accurate estimation of the binding affinity
is a challenging task[29] . The docking scoring functions
are additive in nature, leading to favorable scoring
of high molecular weight molecules[30] . Therefore,
a docking score normalization based on the size of
molecule is required to reduce the bias toward large
compounds. Moreover, in the reverse docking problem
where one ligand is docked to multiple receptors,
the docking scores need to be normalized across
the receptors so that the relative binding affinity
is comparable. For this purpose, a statistical model
for the docking score normalization is developed to
cancel out systematic errors in the docking scoring
functions[17] . The Normalized Docking Score (NDS)
is a relative docking score that is the derivation
of the raw docking score from the background
distribution of a large set of random molecules. The
background distribution depends on both the size
of the ligand and the nature of the receptor. A
more negative value of the NDS indicates a higher
chance of real binding. The normalization starts by
assembling a library of drug-like molecules of varying
number of carbon atoms, which are downloaded from
ZINC (http://zinc.docking.org)[31] . These molecules are
docked to the protein receptors. We found that the
docking score is linearly dependent on the number
of carbon atoms. To save the computational time,
only hundreds of decoy molecules with 5, 10, 15,
20, and 25 carbon atoms for each are selected. The
correlation of the docking score to the number of
carbon atoms is derived from linear regressions. From
the linear fitting curve, the average docking score for
molecules with a certain number of carbon atoms can
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be computed. Based on the fitted average docking score,
a normalized docking score NDS is computed as a zscore:
NDS D .Si i /=;
where Si is the raw docking score for the molecule
with i carbon atoms, i is the fitted average docking
score for the molecules with i carbon atoms, 
is the standard deviation, which is not dependent
on the size of molecules and is approximately 1.0
for all of cases. With the Graphical User Interface
(GUI) application normalization is conducted in high
through-put mode and the standardized docking score
is estimated with R software package embedded in the
POP.
2.4

Electrostatics potential analysis

As docking scores alone may be not sufficient
to prove efficient binding of the drug, a further
electro-chemical analysis is carried out to establish
whether a significantly similar off-target ligand site
is present. Physiochemical features like electrostatic
binding energy of the predicted docking pose,
and comparison of electrostatic potential distribution
between the on- and off-target ligand binding sites,
can be measured with POP. Both the binding energy
and the Electrostatic Potential (EP) are calculated with
APBS. The EP similarity between two binding pockets
is measured by the Pearson correlation between their
EP distributions, as calculated with APBS. The EP
distribution is based on the electrostatic potential grids
in the binding pocket, which contain those grid points
overlapping with atoms of the ligand docked in the
binding pocket. The radius of atoms is fixed as 0.5 nm.
2.5

Integration of biological knowledge

At this point the putative off-targets have reached
a number which permits further investigations over
the biological function. POP facilitates this step
as well, by connecting to PDB through the SOAP
interface and retrieving basic information about
biological function, which now includes protein names
and UniProt accession numbers[32] . The functional
relationships among the on-target and the putative
off-target can be inferred by the co-occurrence of the
protein names in the literature using iHOP literature
network[33] (http://www.ihop-net.org/UniPub/iHOP/),
or Gene Ontology (GO) semantic similarity by
supplying FunSimMat[34] (http://funsimmat.bioinf.mpiinf.mpg.de/index.php) with the UniProt accession
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number. If the putative off-target is involved in, for
example, the same physiological/biological process
as the on-target, it will give a further support to the
prediction. Both of the automatic literature mining
and the GO similarity search have contributed to
the identification of side effect profiles of CETP
inhibitors in our recent study[17] . Following this round
of calculations, the methodology imposes review
of all available clinical and literature information
regarding the top scored receptors. Hopefully, some
of these receptors will be implicated in signaling
pathways affected by the drug. These proteins have
both favorable biological function and binding pockets
which exhibit high affinity to the drug.

3

Results and Discussion

We applied POP to repositioning Human
Immunodeficiency Virus (HIV) protease inhibitor
Nelfinavir to target human kinome for the rational
design of multiple protein kinase inhibitors. Nelfinavir
is an FDA approved antiretroviral medication which
belongs to the class of drugs known as protease
inhibitors. Its primary use is to treat Acquired
Immunodeficiency Syndromes (AIDS). However,
according to recent studies it is also associated with
cancer therapy[35, 36] . In vivo Nelfinavir causes caspasedependent apoptosis and non-apoptotic death, as well
as endoplasmic reticulum stress and autophagy[35] . In
addition, it suppresses tumor cell migration by blocking
angiogenesis[37] and inducing tumor oxygenation of
the tumor[38] . Given its wide spectrum of activity, oral
bioavailability, and fine ADME properties, Nelfinavir is
potentially an ideal candidate for repositioning towards
cancer therapy.
However, there is an uncertainty around the signaling
pathways affected by Nelfinavir. The majority of
published data lead to the assumption that drug may
suppress the Akt signaling pathway[39] . In human,
there are three genes in the Akt family: Akt1, Akt2,
and Akt3. These genes code for enzymes that are
members of the serine/threonine-specific protein kinase
family. Akt1 is involved in cellular survival and protein
synthesis pathways as well as glucose metabolism. Not
surprisingly, Akt1 has been implicated as a major factor
in many types of cancer, including breast, colorectal,
and ovarian cancer[40-42] . Akt2 plays a key role in
glucose transport inductions and is considered as an
important component of Insulin signaling pathway. It is
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also found that some Akt2 alterations lead to ovarian
carcinoma pathogenesis[43] , whereas down-regulation
can block extravasation of circulating breast cancer
cells[44] . This gene is also over-expressed in a subset of
human ductal pancreatic cancers[45, 46] . Akt3 is known
to be stimulated by Platelet-Derived Growth Factor
(PDGF), insulin, and Insulin-like Growth Factor 1
(IGF1)[47] . Thus inhibition of Akt pathway may cause
insulin resistance and diabetes, phenomena observed
as side effects of HIV proteases. However, there is no
experimental proof to support that Nelfinavir can bind
directly to Akt. It is likely that the drug acts upstream
in the signaling pathway[48] .
To identify the human off-targets of Nelfinavir, the
Nelfinavir binding pocket of the HIV protease dimmer
structure (PDB id: 1ohr) was searched against 5985
human protein structures and models using SMAP. Top
ranked SMAP hits (p-value < 10 4 ) are enriched
by multiple members of protein kinase superfamily
(14/18). The SMAP alignments between the PKs and
the Nelfinavir binding sites reveal that co-crystallized
ATP and its competitive inhibitors bind in the vicinity
of the predicted binding sites, as shown as an example
in Fig. 2 for the case of the insulin-like growth factor
1 receptor kinase domain (PDB id: 2OJ9). If amino
acid residues with atomic distances less than 0.5 nm to
the inhibitors are considered as the binding site, around
two-third of these residues overlap between known and
predicated sites for 2OJ9.
Using MD simulation, we found that Nelfinavir might

Fig. 2 The predicted Nelfinavir binding sites in insulinlike growth factor 1 receptor kinase domain (PDB id:
2OJ9) with its co-crystal protein kinase inhibitor 3-[5-(1Himidazol-1-yl)-7-methyl-1H-benzimidazol-2-yl]-4-[(pyridin2-ylmethyl)amino]pyridin-2(1H)-one (BMI). The predicted
binding site residues are represented by green (big) spheres
and BMI by red (small) balls and sticks, respectively.
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weakly interact with multiple members of proteinkinase like superfamily[18] . In addition, the most of
predicted kinase off-targets are on the upstream of Akt1
and Akt2, as shown in the reconstructed AKT pathways
(Fig. 3). Our predictions provide a mechanistic explain
of both diabetes side effect and anti-cancer activity of
Nelfinavir. In our initial work reported in Ref. [18],
the ligand binding site analysis and the protein-ligand
docking were carried out manually. POP makes this
process automatically, thus may facilitate the drug offtarget identification on a large scale.
Moreover, POP offers a new functionality for the
comparison of EP between two binding pockets. EP
similarity provides new evidences to support our
hypothesis as protein kinases are the off-targets of
Nelfinavir. EP similarities between the HIV protease
and protein kinase binding pockets are quantitatively
determined across the human kinome using EP
similarity score. Among 105 members of protein

kinase superfamily, 29% and 8% of them have EP
similarity score larger than 0.50 and 0.80 (p-value =
0), respectively, as shown in Fig. 4. Among top 13
protein kinase off-targets that are predicted by SMAP,
the percentage of them that bear the similar EP to the
HIV protease in the binding pocket is higher than that
of the whole kinome, with 50% and 15% EP similarity
score larger than 0.50 and 0.80, respectively. Thus, the
high EP similarities between these predicted off-targets
and the HIV protease binding pocket through the whole
human kinome is consistent with the high enrichment
of protein kinases in the SMAP off-target search, as
reported in Ref. [18]. As shown in Fig. 5, Nelfinavir
molecule can be fragmented into five moieties: the 2methyl-3-hydroxy-benzamide portion A, the S-phenyl
group B, the tert-butyl carboxamide moiety C, the
lipophilic dodecahydroisoquinoline ring D, and the
central hydroxyl group E. Figure 6 shows the EP
surfaces of the HIV protease and five top ranked protein
kinase off-targets by SMAP. The EP similarity score
is 0.85, 0.81, 0.67, 0.51, and 0.12 for ABL1, Akt2,
IGF1R, EGFR, and EphA2, respectively. In general,
the fragment B of Nelfinavir contacts more positive
charged (blue in the figure) and deeper cavity patches
than the fragment A in the HIV protease binding. The
EP of the predicated protein kinase off-targets shows the
similar pattern to that of the HIV protease. Combining
with the binding site shape similarity and the docking
pose comparisons, the detailed analysis of electrostatic
potential variations in the PK binding pocket will
provide useful clues on optimizing Nelfinavir to target
the multiple PK families.

Fig. 3
Reconstructed PI3K/AKT pathway. Predicted
offtargets are shown as yellow circles. Downstream
activation and inhibition is represented by arrow-headed
and barheaded line, respectively.

Fig. 4
Distribution of electrostatic potential similarity
scores between Nelfinavir binding pockets of HIV protease
and ATP binding pockets of protein kinases.
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system may make it a valuable tool in computational
systems biology and drug discovery.

5

Fig. 5
Structure of Nelfinavir. A, 2-methyl-3hydroxybenzamide moiety; B, S-phenyl group; C, tert-butyl
carboxamide moiety; D, lipophilic dodecahydroisoquinoline
ring; E, central hydroxyl group.

Future Work

One of major drawbacks of the existing implementation
of POP is that it is not flexible enough for users to
incorporate new components. In addition, POP does
not support distributed computing environment that
is required by time-consuming computations such as
MD simulation. We plan to re-implement POP using
scientificworkflow system WINGS (http://www.wingsworkflows.org). Two unique features of WINGS make
it a particularly suitable choice for the proteome-scale
modeling of drug-target interactions. First, WINGS
incorporates semantic constraints about datasets and
workflow components. It will facilitate the integration
of heterogenous data set of chemicals, sequences,
structures, and functions. Second, WINGS is built on
Pegasus, a scientific workflow management system that
allows applications to execute in different environments
including desktops, computer clusters, grids, and
clouds. Under the framework of WINGS, other
computational components, which include all-againstall structure comparison and clustering of putative offtargets, MD simulations of drug-target bindings, and
structure and network visualization tools, can be more
easily incorporated into POP.
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